In another study, Peng et al., used Herceptin (HER) as antibody-conjugated nanoparticles (ACN) to bind extracellularly to the p185 glycoprotein domain of the HER2-positive breast cancer receptor to cause apoptosis in tumour cells or to stop the cell cycle progression. Here, EIF3A is linked to neoplasm.